Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 8/20 | 0.48 |
| ▸ | CA1 | P00915 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | G6PD | P11413 | 2/20 | 0.42 |
| ▸ | FGF1 | P05230 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18819802 | 1.00 | CA9 (0.48) | CA9CA1CA2MMP9MMP12 | |
| SCHEMBL17099845 | 1.00 | CA9 (0.48) | CA9CA1CA2MMP9MMP12 | |
| SCHEMBL17549373 | 1.00 | CA9 (0.48) | CA9CA1CA2MMP9MMP12 | |
| SCHEMBL2785750 | 1.00 | CA9 (0.48) | CA9CA1CA2MMP9MMP12 | |
| SCHEMBL2235789 | 1.00 | CA9 (0.48) | CA9CA1CA2MMP9MMP12 | |
| SCHEMBL17179731 | 1.00 | CA9 (0.48) | CA9CA1CA2MMP9MMP12 | |
| SCHEMBL14906758 | 1.00 | CA9 (0.48) | CA9CA1CA2MMP9MMP12 | |
| SCHEMBL18517532 | 1.00 | CA9 (0.48) | CA9CA1CA2MMP9MMP12 | |
| SCHEMBL7150973 | 0.99 | CA9 (0.46) | CA9CA1CA2MMP9MMP12 | |
| SCHEMBL7150978 | 0.99 | CA9 (0.46) | CA9CA1CA2MMP9MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197633-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| US-20240180951-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4321504-A1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| EP-4321503-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED THEREBY, PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME, PREPARATION THEREOF, AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| EP-4276090-A1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2023-11-15 | — | — | EP | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| CN-106967213-B | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2019-11-05 | — | — | CN | disclosed |
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2019-10-08 | — | — | US | disclosed |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| WO-2011066653-A1 | SALACINOL AND PONKORANOL HOMOLOGUES, DERIVATIVES THEREOF, AND METHODS OF SYNTHESIZING SAME | SIMON FRASER UNIVERSITY (CA) | 2011-06-09 | — | — | WO | disclosed |
| CN-101591364-A | Amino sugar derivative, its method for making and medicinal use thereof | UNIV CHINA PHARMA (CN) | 2009-12-02 | — | — | CN | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| EP-0650974-A1 | Acylaminosaccharide derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1995-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180951-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | LIPG, PHOSPHO1, LDLR | CA9 3249/4885CA1 4848/4885CA2 4626/4885 |
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, MRPS18A | CA9 2725/4885CA1 2605/4885CA2 4307/4885 |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, COG8 | CA9 2429/4885CA1 2620/4885CA2 4145/4885 |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | MRPL38, CXCL8, ALG8 | CA9 2414/4885CA1 2687/4885CA2 4355/4885 |
| US-20240197633-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | LIPG, LDLR, LIPA | CA9 3121/4885CA1 4846/4885CA2 4623/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | CA9 4423/4885CA1 3481/4885CA2 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.